MDR1, MRP, topoisomerase IIα/β, and cyclin A gene expression in acute and chronic leukemias

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Beck, J ^a   Niethammer, D ^a   Gekeler, V ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

Cyclin A; Leukemias; MDR1 P glycoprotein; MRP; Multidrug resistance; Topoisomerases

Indexed keywords

ABC TRANSPORTER; COMPLEMENTARY DNA; CYCLIN A; DNA TOPOISOMERASE (ATP HYDROLYSING); GLYCOPROTEIN P; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BLAST CELL CRISIS; BONE MARROW; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029820407     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Pui C-H. Childhood leukemias. New Engl J Med 1995; 332: 1618-1630.
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. New Engl J Med 1995; 333: 1052-1057.
3. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implication for systemic therapy. Cancer Res 1984; 44: 3643-3653.
4. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
5. Gottesman MM, Schoenlein PV, Currier SJ, Bruggemann EP, Pastan I. Biochemical basis for multidrug resistance in cancer. Biochem Mol Aspects Sel Cancers 1991; 1: 339-371.
6. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
7. Grant C, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
8. Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A. Altered DNA topoisomerase II activity in chinese hamster cells resistant to topoisomerase inhibitors. Cancer Res 1986; 46: 3075-3081.
9. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989; 86: 9431-9435.
10. Fernandes DJ, Danks MK, Beck WT. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 1990; 29: 4235-4241.
11. DeJong S, Zijlstra JG, de Vries EGE, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1990; 50: 304-309.
12. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Drug resistance associated with altered topoisomerase II. Adv Enzyme Regul 1993; 33: 113-127.
13. Mirski SEL, Evans CD, Almquist KC, Slovak ML, Cole SPC. Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993; 53: 4866-4873.
14. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994; 54: 152-158.
15. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 1995; 55: 78-82.
16. MA DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR. Detection of a multidrug resistant phenotype in acute nonlymphoblastic leukaemia. Lancet 1987; 17: 135-137.
17. Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo AT. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989; 74: 1388-1395.
18. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
19. Niethammer D, Diddens H, Gekeler V, Frese G, Handgretinger R, Henze G, Schmidt H, Probst H. Resistance to methotrexate and multidrug resistance in childhood malignancies. Adv Enzyme Regul 1989; 29: 231-245.
20. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T, Akiyama S. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868-873.
21. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990; 82: 1133-1140.
22. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
23. Gekeler V, Frese G, Noller A, Handgretinger R, Wilisch A, Schmidt H, Muller C, Dopfer R, Klingebiel T, Diddens H, Probst H, Niethammer D. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase π gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 1992; 66: 507-517.
24. Goasguen JE, Dossot J-M, Fardel O, Mee FL, Gall EL, Leblay R, LePrise PY, Chaperon J, Fauchet R. Expression of the multidrug resistance associated P-glycoprotein in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-2398.
25. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase IIα/β and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 1995; 89: 356-363.
26. Mattern J, Volm M. Multiple pathway drug resistance (review). Int J Oncol 1993; 2: 557-561.
27. Gekeler V, Beck J, Noller A, Wilisch A, Frese G, Neumann M, Handgretinger R, Ehninger G, Probst H, Niethammer D. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 1994; 69: S19-S24.
28. Beck J, Niethammer D, Gekeler V, High mdr1- and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 1994; 86: 135-142.
29. Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 1996; (in press).
30. Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, Hofmann J, Thaler J. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751-1758.
31. Brophy NA, Marie JP, Rojas VA, Warnke RA, McFall PJ, Smith SD, Sikic BI. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 1994; 8: 327-335.
32. Kang Y-K, Zhan Z, Regis J, Robey R, Meadows B, Dichstein B, Lee JS, Otsuki T, Stetler-Stevenson M, Jaffe ES, Solomon D, Wilson WH, Fojo A, Bates SE. Expression of mdr-1 in refactory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995; 86: 1515-1524.
33. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995; 1: 81-93.
34. Burger H, Nooter K, Zaman GJ, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G. Expression of the multidrug resistance-associated protein (mrp) in acute and chronic leukemias. Leukemia 1994; 8: 990-997.
35. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance associated protein (MRP) in acute leukemia. Leukemia 1994; 8: 2163-2168.
36. Zhou DC, Hoang NL, Delmer A, Faussat AM, Russo D, Zittoun R, Marie JP. Expression of resistance genes in acute leukemia. Leuk Lymphoma 1994; 1: 27-30.
37. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia, Blood 1995; 85: 186-193.
38. Ludescher C, Eisterer W, Hilbe W, Gotwald M, Hofmann J, Zabernigg A, Cianfriglia M, Thaler J. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 1995; 9: 350-356.
39. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154-8160.
40. Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK. Differences between normal and rastransformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res 1990; 50: 2901-2908.
41. Khélifa T, Casabianca-Pignéde M-R, René B, Jacquemin-Sablon A. Expression of topoisomerase IIα and β in Chinese hamster lung cells resistant to topoisomerase II inhibitors. Mol Pharmacol 1994; 46: 323-328.
42. Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astradi-Ricotti GBC, Bottiroli G. Topoisomerase IIα and β in human tumor cells grown in vitro and in vivo. Anticancer-Res 1992; 12: 2093-2100.
43. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994; 83: 517-530.
44. Van der Zee AGJ, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EGE. Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 1994; 54: 749-755.
45. Boege F, Gieseler F, Biersack H, Meyer P. The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies. Eur J Clin Chem Clin Biochem 1992; 30: 63-68.
46. Hochhauser D, Harris AL. The role of topoisomerase IIα and β in drug resistance. Cancer Treat Rev 1993; 19: 181-194.
47. Potmesil M, Hsiang Y-H, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, Traganos F, Silber R. Resistance of human leukemic and normal lympocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 3537-3543.
48. Silber R, Potmesil M, Bank BB. Studies on drug resistance in chronic lymphocytic leukemia. Adv Enzyme Regul 1989; 29: 267-276.
49. Boer R, Gekeler V. Chemosensitizers in tumor therapy: new compounds promise better efficacy. Drugs of the Future 1995; 20: 499-509.
50. Gekeler V, Ise W, Boer R, Beck J, Sanders KH, Zimmermann P, Ulrich WR. Modulation of MRP-associated MDR. (#2044) Proc Am Assoc Cancer Res 1995; 36: 343.
51. Grunicke H, Hofmann J, Utz I, Überall F. Role of protein kinases in antitumor drug resistance. Ann Hematol 1994; 69: S1-S6.